Another Canadian cannabis company has fallen victim to the weak market, with Zenabis Global (TSX:ZENA) announcing a significant cut to its workforce. 

On Wednesday (March 11), the Vancouver-based licensed producer (LP), which has operations across Canada, confirmed it has let go of 22 percent of its overall workforce.

Shares of the company quickly fell in Thursday’s (March 12) trading session following the news. Zenabis opened at C$0.06, but midway through the trading day the firm had seen a drop of 21.43 percent in value, resulting in a price per share of C$0.05.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

In a statement, Zenabis CEO Kevin Coft said the firm is aiming to become cash flow positive in 2020 through this operational efficiency measure.

Given the current climate for cannabis sales in Canada, the company does not plan to expand or create more growing options for itself; it believes its current capacity is enough to meet demand.

Although Zenabis expressed excitement about the expected growth Canadian cannabis sales could see from an increase in the availability of edible and infused products, the company told investors it anticipates that sales from the unregulated cannabis market will continue to impact wholesale prices, as well as the legal cannabis market’s expansion.

Zenabis joins a growing list of marijuana operations in Canada that have had to face cuts amid the financial realities of the capital markets.

Most recently, Canopy Growth (NYSE:CGC,TSX:WEED) announced plans to shut down operations at two facilities located in Aldergrove and Delta, BC. It also terminated approximately 500 positions.

In February, Tilray (NASDAQ:TLRY) confirmed it would let go of about 10 percent of its workforce. Similar reductions have been seen at Aurora Cannabis (NYSE:ACB,TSX:ACB) and The Supreme Cannabis Company (TSX:FIRE,OTCQX:SPRWF).

Charles Taerk, CEO of Faircourt Asset Management, a sub-advisor to Ninepoint Partners’ cannabis-focused fund, told the Investing News Network (INN) that the cuts from Canopy in particular were no surprise and will actually be beneficial to the firm in the long term.

“I think that there are many companies that are finding it difficult to operate in this capital-constrained environment,” he told INN.

Zenabis became part of another larger trend in the Canadian cannabis market when its CEO suddenly departed. In December, the firm notified investors that Andrew Grieve was out as its executive leader.

“Most of these cuts for costs will actually turn out to be positive and help the lifespan of these companies,” Nawan Butt, a portfolio manager at Purpose Investments, previously told INN in a wide-ranging conversation about the cannabis market.

Zenabis was also in the news last year when it faced pressure in the markets as it attempted to defend a rights offering plan.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
  • The Cannabis Derivatives are derived from Avicanna’s cultivation and extraction infrastructure in Santa Marta, Colombia designed to supply partner companies and the manufacture of Avicanna’s own finished products.

Avicanna Inc. (” Avicanna ” or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that, through its majority owned Colombian subsidiary, Santa Marta Golden Hemp S.A.S. (“ SMGH ”), it has completed a commercial exports of CBD Isolate and CBD full spectrum psychoactive cannabis resin (the “ Cannabis Derivatives ”) to a leading Chilean homeopathic and naturopathic pharmaceutical company.

The Cannabis Derivatives, branded as Aureus™, are cultivated, extracted, and manufactured by SMGH. In addition, for Avicanna’s global input needs, SMGH also supplies other pharmaceutical and cosmetics companies with cannabinoids including CBD, THC, and rare cannabinoids such as CBG in addition to supplying global cultivation companies with standardized and feminized seeds. This new export to Chile is a recurring order and part of on-going relationship with an established homeopathic Chilean company.

Keep reading... Show less

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX:WEED, NASDAQ:CGC) will release its financial results for the second quarter fiscal year 2022 ended September 30, 2021 before financial markets open on November 5, 2021 .

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, announced today the opening of a new Sunnyside dispensary in Wyomissing, Pennsylvania. Wyomissing will be Cresco Labs’ fifth dispensary in Pennsylvania and 38 th nationwide.

This press release features multimedia. View the full release here:

Keep reading... Show less

The world of cannabis consumption is set to change radically, thanks in large part to the advancement of state-of-the-art research on the plant itself.

Medical cannabis products have already allowed many new users to discover the plant’s potential, but decisive research will help build a foundation for more sophisticated medical offerings.

Keep reading... Show less


Adastra Holdings Ltd. (formerly Phyto Extractions Inc.) (CSE: XTRX) (FRA: D2EP) (“Adastra”, or the “Company”) is pleased to announce that it has retained Hybrid Financial Ltd. (“Hybrid”) to provide marketing services to the Company. Hybrid has been engaged to heighten market and brand awareness for Adastra and to broaden the Company’s reach within the investment community.

Keep reading... Show less